🎉 M&A multiples are live!
Check it out!

Immunic Valuation Multiples

Discover revenue and EBITDA valuation multiples for Immunic and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Immunic Overview

About Immunic

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.


Founded

2003

HQ

United States of America
Employees

77

Website

imux.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$53.3M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Immunic Financials

Immunic has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Immunic achieved revenue of n/a and an EBITDA of -$97.9M.

Immunic expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Immunic valuation multiples based on analyst estimates

Immunic P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$99.1M -$97.9M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$120M -$93.6M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Immunic Stock Performance

As of April 15, 2025, Immunic's stock price is $1.

Immunic has current market cap of $88.0M, and EV of $53.3M.

See Immunic trading valuation data

Immunic Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$53.3M $88.0M XXX XXX XXX XXX $-0.94

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Immunic Valuation Multiples

As of April 15, 2025, Immunic has market cap of $88.0M and EV of $53.3M.

Immunic's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Immunic's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Immunic and 10K+ public comps

Immunic Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $53.3M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.5x XXX XXX XXX
P/E -0.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Immunic Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Immunic Valuation Multiples

Immunic's NTM/LTM revenue growth is n/a

Immunic's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.

Over next 12 months, Immunic's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Immunic's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Immunic and other 10K+ public comps

Immunic Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -1% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Immunic Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Immunic M&A and Investment Activity

Immunic acquired  XXX companies to date.

Last acquisition by Immunic was  XXXXXXXX, XXXXX XXXXX XXXXXX . Immunic acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Immunic

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Immunic

When was Immunic founded? Immunic was founded in 2003.
Where is Immunic headquartered? Immunic is headquartered in United States of America.
How many employees does Immunic have? As of today, Immunic has 77 employees.
Who is the CEO of Immunic? Immunic's CEO is Dr. Daniel Vitt, PhD.
Is Immunic publicy listed? Yes, Immunic is a public company listed on NAS.
What is the stock symbol of Immunic? Immunic trades under IMUX ticker.
When did Immunic go public? Immunic went public in 2014.
Who are competitors of Immunic? Similar companies to Immunic include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Immunic? Immunic's current market cap is $88.0M
Is Immunic profitable? Yes, Immunic is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.